Log In
Friday 28th October 2016

Three bowel cancer drugs rejected

5th September 2011

The National Institute for Health and Clinical Excellence has not given its approval for the use of three drugs to treat advanced bowel cancer.

NICE said the use of the drugs cetuximab, bevacizumab and panitumumab was too expensive when weighed up against their benefits. Andrew Dillon, NICE’s chief executive, said: "We have already recommended six treatments for various stages of colorectal cancer and are disappointed not to be able to recommend cetuximab, bevacizumab and panitumumab for this stage, but we have to be confident that the benefits justify the cost of the drugs. At present, the independent appraisal committee...does not feel it has enough clear evidence...to be able to recommend these drugs for use on the NHS."


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2016